A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.

Trial Profile

A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Cediranib (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Jan 2011 Actual initiation date (Mar 2004) added as reported by ClinicalTrials.gov.
    • 11 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top